Enveric Biosciences (ENVB) Stock Price, News & Analysis

Company Overview

Enveric Biosciences, Inc. is a clinical-stage biotechnology company focused on the discovery and development of first-in-class psychedelic-inspired therapeutics for oncology supportive care. The company’s research strategy centers on harnessing novel analogs of psychedelic compounds to address debilitating side effects of cancer treatments, including chemotherapy-induced peripheral neuropathy, cancer‐related fatigue, anxiety and post-traumatic stress disorder in oncology patients.

Enveric’s pipeline features proprietary molecules engineered for improved safety, tolerability and pharmacokinetic profiles compared with naturally occurring psychedelics. Its lead program, ENB-101, is a synthetic psilocybin analog in Phase 2 development for chemotherapy-induced peripheral neuropathy, while additional candidates are progressing toward clinical evaluation in cancer-related fatigue and anxiety. These programs are supported by preclinical data demonstrating neuroprotective and anti-inflammatory properties in relevant animal models.

Founded in 2019 and headquartered in Miami, Florida, Enveric maintains research and manufacturing operations in the United States and Europe. The company has initiated multiple clinical trials across North America and the European Union and collaborates with academic institutions, contract research organizations and patient advocacy groups to advance its oncology supportive care platform. Strategic partnerships aim to accelerate development timelines and expand access to its therapeutic candidates worldwide.

Enveric’s leadership team combines decades of experience in neuroscience, oncology drug development and pharmaceutical commercialization. The executive team and board of directors include veterans of leading biopharmaceutical companies who have guided programs through regulatory approval and global launches. Through its scientific advisory board, Enveric engages experts in neurology, oncology and psychedelic science to inform trial design and foster innovation across its therapeutic pipeline.

Key Stats

• Today's Range: $1.31 to $1.36
• 50-Day Range: $1.17 to $1.43
• 52-Week Range: $1.01 to $11.55
• Volume: 61,224 shs
• Average Volume: 777,124 shs
• Market Capitalization: $3.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Enveric Biosciences Stock Analysis - MarketRank™

Enveric Biosciences scored higher than 54% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Enveric Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Enveric Biosciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Enveric Biosciences are expected to grow in the coming year, from ($31.18) to ($21.14) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Enveric Biosciences is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enveric Biosciences is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enveric Biosciences has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.57% of the float of Enveric Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Enveric Biosciences has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enveric Biosciences has recently increased by 17.78%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enveric Biosciences does not currently pay a dividend.

Dividend Growth

Enveric Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.57% of the float of Enveric Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Enveric Biosciences has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enveric Biosciences has recently increased by 17.78%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: N/A

News Sentiment

Enveric Biosciences has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Enveric Biosciences this week, compared to 0 articles on an average week.

Search Interest

Only 2 people have searched for ENVB on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

1 people have added Enveric Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Enveric Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.10% of the stock of Enveric Biosciences is held by insiders.

Percentage Held by Institutions

Only 13.82% of the stock of Enveric Biosciences is held by institutions.

ENVB Stock Analysis - Frequently Asked Questions

How have ENVB shares performed this year?

Enveric Biosciences' stock was trading at $5.3760 at the beginning of 2025. Since then, ENVB stock has decreased by 75.6% and is now trading at $1.31.

How were Enveric Biosciences' earnings last quarter?

Enveric Biosciences, Inc. (NASDAQ:ENVB) posted its quarterly earnings results on Wednesday, May, 14th. The company reported ($1.22) EPS for the quarter, beating analysts' consensus estimates of ($3.45) by $2.23.

When did Enveric Biosciences' stock split?

Enveric Biosciences's stock reverse split before market open on Wednesday, January 29th 2025.The 1-15 reverse split was announced on Tuesday, January 21st 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Enveric Biosciences?

Shares of ENVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Enveric Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enveric Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), Broadcom (AVGO), ServiceNow (NOW) and Adobe (ADBE).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENVB
• CIK: 890821
• Web: jaypharma.co
• Phone: (239) 302-1707
• Fax: 732-243-9254
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Enveric Biosciences: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Potential Upside/Downside: +663.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($38.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.57 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -250.28%
• Return on Assets: -195.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.08
• Quick Ratio: 4.08

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.35 per share
• Price / Book: 0.56

Miscellaneous

• Outstanding Shares: 2,470,000
• Free Float: 2,445,000
• Market Cap: $3.24 million
• Optionable: Not Optionable
• Beta: 0.54